Shubhayu Sinharoy brings extensive experience from both entrepreneurial leadership and strategic investment roles in the pharmaceutical and healthcare sectors.

As Co-founder, Board Member, and COO of Calyptus Pharmaceuticals, Shubhayu led the specialty pharmaceuticals company in developing sterile therapeutic products for acute care hospitals, community clinics, and retail pharmacies. He also spearheaded business development efforts, negotiating and executing strategic partnerships, licensing agreements, and commercial arrangements with pharmaceutical companies. Calyptus secured multiple FDA approvals and successfully commercialized several complex injectable products, culminating in the acquisition of its portfolio and pipeline assets by strategic pharma in 2022.

Currently, as Managing Member of Tridevi Ventures, he has established a strong track record of investing in healthcare technology, biopharmaceuticals, diagnostics, and medical devices.

Prior to co-founding Calyptus Pharmaceuticals, Shubhayu served as Head of M&A and Business Development for Dr. Reddy's Laboratories North America, where he spearheaded multiple transactions, including the $350 million acquisition of Teva's product portfolio. He previously held roles in M&A at TE Connectivity, as well as strategy consulting and engineering positions at L.E.K. Consulting and Eaton.

Shubhayu holds an M.B.A. from the Wharton School at the University of Pennsylvania, a Master of Science in Engineering from Michigan Technological University, and a Bachelor's degree in Engineering from the Indian Institute of Technology Madras.